Arkolith/Insider Trading/ADXS/Form 4

Israel Biotech Fund I, L.P.

Director, 10% OwnerAyala Pharmaceuticals, Inc. (ADXS) · full profile →Form 4 · filed Mar 6, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
0 non-derivative · 6 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 1, 2024Option exercise(M)3.8M——4.1M
Mar 1, 2024Option exercise(M)3.8M——9.7M
Mar 1, 2024Option exercise(M)2.3M——13.5M
Mar 1, 2024Option exercise(M)1.5M——11.2M
Mar 1, 2024Option exercise(M)2.3M——7.8M
Mar 1, 2024Option exercise(M)1.5M——5.6M

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001178913-24-000828) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML